Company / Operating Income
GYRE THERAPEUTICS, INC. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$11.5M
FY2025
5-year range
-$87.9M / $16.2M
FY2021-FY2025
Trend
-28.9%
vs FY2024
Sector context
#53 of 204
Health Care
What the data says
At $11M, GYRE THERAPEUTICS, INC.'s operating income ranks #53 of 204 in the Health Care sector. Improved from $9M to $11M over the past 2 years.
Based on SEC 10-K filings.
$11M in FY2025 with a 3-year CAGR of +7.7%.
Improved from $9M to $11M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- +7.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#53 of 204 in Health CareTop 26% of 204This company $11.5M Sector average $107.8M
▼
-89.3% below sector average
Key checks
Key Insights
- 3-year CAGR of +7.7%, indicating consistent growth.
- In FY2025, operating income decreased 28.9% year-over-year.
- Ranks #53 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2024.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.5M | -28.9% |
| FY2024 | $16.2M | +75.6% |
| FY2023 | $9.2M | +0.0% |
| FY2022 | $9.2M | +110.5% |
| FY2021 | -$87.9M | -53.5% |
| FY2020 | -$57.3M | +0.0% |
| FY2019 | -$57.3M | -162.5% |
| FY2018 | -$21.8M | +0.0% |
| FY2017 | -$21.8M | -6.9% |
| FY2016 | -$20.4M | -47.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026